Cancer Treatments
Search documents
Market Downturn Hits Various Sectors Hard
Financial Modeling Prep· 2025-11-12 00:00
Company Performance - Salarius Pharmaceuticals, Inc. experienced a dramatic drop of approximately 49.5%, with its stock price falling to $1.01, reflecting volatility in the biotechnology sector focused on cancer treatments [1][6] - Vor Biopharma Inc. saw its stock price halve, decreasing by 47.77% to $9.82, following a significant market correction from a yearly high of $65.8, despite securing a $100 million offering [2] - Outset Medical, Inc. witnessed a 46.89% decline in its stock price to $6.40, indicating broader challenges within the healthcare sector, particularly for medical device companies [3] - Epsium Enterprise Limited's stock price decreased by 43.1% to $3.27, with a significant range in its stock price over the past year, reflecting market adjustments in the alcoholic beverages sector [4] Market Sentiment - The significant price movements highlight the volatility and challenges faced by companies across various sectors, prompting market participants to monitor these companies for signs of recovery or further adjustments [5]
Johnson & Johnson (JNJ) Is Leading The Industry In Cancer Treatments, Says Jim Cramer
Yahoo Finance· 2025-10-02 07:08
We recently published 5 Stocks That Were On Jim Cramer’s Radar As He Discussed AI. Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer recently discussed. Johnson & Johnson (NYSE:JNJ) is one of the most diversified healthcare companies in the world. The firm operates in the pharmaceutical, medical devices, and other industries. Cramer previously discussed the stock on September 11th, when he wondered whether the major “litigation overhang” surrounding the firm actually involved an “overplayed” ha ...